


Appendix 1

Table Quality assessment of included studies


NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE FOR COHORT STUDIES										
STUDY	SELECTION				COMPARABILITY	OUTCOME				
	Representativeness of the exposed cohort	Selection of the non-exposed cohort	Ascertainment of exposure	Demonstration that outcome of interest was not present at start of study	Comparability of Cohorts Based on the Design or Analysis Maximum: ☆☆	Assessment of outcome	Was follow-up long enough for outcomes to occur	Adequacy of follow up of cohorts	SCORE	Evidence quality
Rinkel et al	☆	☆	☆	☆	☆☆	☆	☆	☆	9	Low risk
NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE FOR CASE-CONTROL STUDIES										
STUDY	SELECTION				COMPARABILITY	EXPOSURE				
	Is the case definition adequate?	Representativeness of the cases	Selection of Controls	Definition of Controls	Comparability of cases and controls based on the design or analysis (Maximum: ☆☆)	Same method of ascertainment for cases and controls	Non-Response rate	Ascertainment of exposure	SCORE	Evidence quality
Gonzales et al.	☆	☆	☆	☆	☆	☆	☆	☆	8	Low risk
Aryan et al.	☆	☆	☆	☆	☆☆	☆	☆	☆	9	Low risk

Moosaie et al.	☆	☆	☆	☆	☆	☆	☆	☆	8	Low risk
NEWCASTLE - OTTAWA QUALITY ASSESSMENT SCALE FOR CROSS-SECTIONAL STUDIES										
STUDY	SELECTION				COMPARABILITY	OUTCOME				
	Representativeness of the sample	Sample size	Non-respondents	Ascertainment of the exposure (risk factor)	The subjects in different outcome groups are comparable, based on the study design or analysis. Confounding factors are controlled.	Assessment of outcome	Statistical test		SCORE	Evidence quality
					Maximum: ☆☆					
Nanda et al.	☆	☆	☆	☆	☆☆	☆	☆		8	Low Risk


Appendix 2



Funnel Plot of Association between ApoB levels and Neuropathy/DFU



Funnel Plot of Association between ApoA1 levels and Neuropathy/DFU



Funnel Plot of Association between ApoB/ApoA1 Ratio and Neuropathy/DFU

Appendix 3

Database: PubMed

("Diabetic Neuropathies"[Mesh] OR "diabetic neuropathy" OR "peripheral neuropathy" OR "neuropathic complications")

AND

("Apolipoproteins A"[Mesh] OR "Apolipoprotein A1" OR "ApoA1")

AND

("Apolipoproteins B"[Mesh] OR "Apolipoprotein B" OR "ApoB")

AND

("Apolipoprotein B/A1 Ratio" OR "ApoB/ApoA1" OR "ApoB:ApoA1")

Database: ProQuest / EBSCOhost / Medline (search adjusted per platform syntax)

("diabetic neuropathy" OR "diabetic peripheral neuropathy" OR "peripheral nerve complications")

AND

("Apolipoprotein A1" OR "ApoA1")

AND

("Apolipoprotein B" OR "ApoB")

AND

("ApoB/ApoA1 ratio" OR "ApoB:ApoA1" OR "ApoB to ApoA1")

Search filters:

- No date restrictions
- No language restrictions (non-English studies translated using Google Translate)
- Human studies only
- Adult population (≥ 18 years)

Date of search execution: December 7, 2024

Peer Review of Electronic Search Strategies (PRESS) 2015 Checklist
Completed for PubMed search strategy

Item	Assessment	Comments
1. Translation of research question	Yes	Concepts clearly mapped to subject headings and keywords
2. Boolean and proximity operators	Yes	Appropriate use of AND/OR operators to combine concepts
3. Subject headings (e.g., MeSH)	Yes	Correct MeSH terms applied for 'diabetic neuropathy' and 'apolipoproteins'
4. Text word searching	Yes	Common synonyms and variants (e.g., ApoA1, ApoB) included
5. Spelling, syntax, and line numbers	Yes	Search syntax verified for correct spelling and logic
6. Limits and filters used appropriately	Yes	No limits on language or date; filters for adult population only
7. Overall search strategy structure	Yes	Logical and replicable; pilot-tested for yield

Date Reviewed: December 6, 2024

Review Outcome: No revisions required

Appendix 4

PRISMA 2020 Checklist

This checklist outlines where each PRISMA 2020 item is addressed in the manuscript titled 'Association Between ApoA1, ApoB and The ApoB/ApoA1 Ratio with The Risk of Diabetic Neuropathy: A Systematic Review and Meta-Analysis'.

Section/Topic	Item	Checklist Item	Reported on Page
TITLE	1	Identify the report as a systematic review, meta-analysis, or both.	Title page Page 1
ABSTRACT	2	Provide a structured summary including background, objectives, data sources, eligibility criteria, participants, interventions, study appraisal, synthesis methods, results, limitations, conclusions, and implications.	Page 1
INTRODUCTION	3	Rationale: Describe the rationale for the review in the context of existing knowledge.	Page 1-2
	4	Objectives: Provide an explicit statement of the objective(s).	Page 2
METHODS	5	Eligibility criteria: Specify inclusion and exclusion criteria.	Page 2
	6	Information sources: Describe all sources of information (e.g., databases).	Page 2
	7	Search strategy: Present full search strategy for at least one database.	Page 2-3 (PRESS Checklist)
	8	Selection process: State the process	Page 2-3

		for selecting studies.	
	9	Data collection process: Describe method of data extraction.	Page 2-3
	10	Data items: List and define all outcomes and variables for which data were sought.	Page 2-3
	11	Study risk of bias assessment: Describe methods used to assess bias.	Page 3
	12	Effect measures: Specify for each outcome the effect measure(s).	Page 3
	13	Synthesis methods: Describe methods of handling data and combining results.	Page 3
	14	Reporting bias assessment: Describe any methods used to assess publication bias.	Page 3
	15	Certainty assessment: Describe any methods to assess the certainty of evidence.	Not applicable
RESULTS	16	Study selection: Provide numbers of studies screened, assessed, and included (with reasons).	Page 4
	17	Study characteristics: Cite each study and present characteristics.	Page 4-5 + Table 1
	18	Risk of bias in studies: Present assessments of risk of bias.	Page 5 + Table 2

	19	Results of individual studies: Present summary data for each study.	Page 4-7
	20	Results of syntheses: Present overall results with heterogeneity metrics (e.g., I^2).	Page 5-7
	21	Reporting biases: Present results of assessment of risk of bias due to missing results.	Page 5
	22	Certainty of evidence: Present assessments of the certainty of evidence.	Not reported
DISCUSSION	23	Summary of evidence: Summarize main findings including strength of evidence.	Page 8
	24	Limitations: Discuss limitations of included evidence and review process.	Page 9
	25	Conclusions: Provide a general interpretation and implications.	Page 9
OTHER INFORMATION	26	Registration and protocol: Provide registration info and protocol access.	Not applicable
	27	Support: Describe sources of support.	Acknowledgments
	28	Competing interests: Declare any competing interests.	Page 9
	29	Availability of data, code, and other materials.	Page 9 + Supplement